VeriSilicon and Innobase Collaboratively Launched Second-Generation Yunbao Series 5G RedCap/4G LTE Dual-Mode Modem IP
23.1.2025 01:00:00 CET | Business Wire | Press release
Advancing cellular mobile communication technology innovation and accelerating the lightweight 5G application adoption
VeriSilicon (688521.SH) today announced the joint launch of the second-generation Yunbao series 5G RedCap/4G LTE dual-mode modem IP, Yunbao 2, in collaboration with Innobase, a wireless communication technology and chip provider. This new modem IP has successfully completed production validation.
The newly launched modem IP integrates and reuses 4G and 5G hardware accelerators, delivering industry-leading performance in terms of area and power consumption. This IP complies with the 3GPP 5G Rel-17 standard and supports both 5G RedCap and 4G LTE FDD/TDD, achieving uplink and downlink transmission rates of 170 Mbps and 120 Mbps, respectively. It also supports multi-SIM standby and features key 5G capabilities such as Ultra-Reliable Low Latency Communication (URLLC), 5G LAN, and network slicing. Furthermore, chips developed using the Yunbao 2 modem IP can be paired with Innobase’s production-validated high-performance dual-mode RF chips, enabling seamless product-level integration and significantly accelerating the commercialization process for customers.
Under the guidance and organization of the IMT-2020 (5G) Promotion Group, the Yunbao series has successfully completed 5G RedCap terminal equipment and field performance testing with Nokia Shanghai Bell and ZTE. Additionally, it has completed interoperation tests between 5G RedCap terminals and base stations in collaboration with partners. These tests were conducted strictly adhering to the standards set by the Promotion Group, covering the full range of 5G RedCap terminal functionalities and performance metrics. The results thoroughly validated the overall capabilities of the Yunbao series, as well as its seamless interoperability with multiple network equipment vendors.
“The commercialization of RedCap in China has entered a rapid growth phase. As a new 5G variant defined under the 3GPP Rel-17 standard, RedCap features low cost, low latency, private network, and efficient spectrum utilization, making it an ideal solution for wearable devices, industrial IoT, and mass-market smartphones,” said Lu Wenbo, Senior Vice President of Innobase. “Innobase has introduced a variety of mass-production-ready products, including 5G IoT modules, MiFi devices, and mass-market 5G smartphones, which have successfully validated the Yunbao series IP at the product level. In the future, Innobase will leverage its extensive expertise in cellular communication technologies to develop the Yunbao X series featuring ultra-low-cost and ultra-low-power designs, to address the needs of consumer electronics and IoT applications. With the RedCap market rapidly evolving, we are excited to collaborate with VeriSilicon to deliver more advanced 5G multi-mode modem IP solutions to our customers.”
“The cost and performance of 5G RedCap chips are comparable to those of 4G, further expanding the boundaries of existing 4G application scenarios,” said Wiseway Wang, Executive Vice President, General Manager of Custom Silicon Platform Division of VeriSilicon. “Through our collaboration with Innobase, VeriSilicon is able to offer production-validated 4G/5G RedCap dual-mode IPs, further strengthening our existing IP ecosystem. VeriSilicon remains committed to driving innovation in low-power, high-performance wireless communication technologies, providing comprehensive wireless communication solutions, including RF, baseband, and protocol stacks, for IoT applications. Looking ahead, VeriSilicon will continue working closely with industry partners to build a global cellular communication ecosystem and contribute to an intelligent, connected future.”
About Innobase
Innobase is a leading fabless chip design company for cellular mobile communications. It designs chipset of 4G/5G and future 6G, including Baseband, RF, and PMIC for mobile terminals. Its dual mode chipset of 4G LTE/5G RedCap is commercialized with customers including telecom operators, IoT module makers, and mobile phone IDHs/ODMs. For more information, please visit: www.innobase.com.cn
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121582002/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom